We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novavax Inc | NASDAQ:NVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.19 | -3.85% | 4.74 | 4.73 | 4.74 | 5.045 | 4.725 | 4.93 | 4,814,474 | 22:45:08 |
Conference details are as follows:
Citi 15th Annual BioPharma Virtual Conference
Date: | September 10, 2020 |
Event: | Investor meetings only |
H.C. Wainwright 22nd Annual Global Investment Conference
Date: | September 14, 2020 |
Time: | 9:30 a.m. U.S. Eastern Time (ET) |
Event: | Corporate presentation and investor meetings |
Live Webcast: | www.novavax.com, “Investors”/ “Events” |
Cantor Virtual Global Healthcare Conference
Date: | September 15, 2020 |
Time: | 11:20 a.m. U.S. Eastern Time (ET) |
Event: | Fireside chat and investor meetings |
Live Webcast: | www.novavax.com, “Investors”/ “Events” |
Morgan Stanley Virtual 18th Annual Global Healthcare Conference
Date: | September 16, 2020 |
Time: | 12:30 p.m. U.S. Eastern Time (ET) |
Event: | Fireside chat and investor meetings |
Live Webcast: | www.novavax.com, “Investors”/ “Events” |
Leerink CyberRx Series: Vaccine Forum
Date: | September 23, 2020 |
Time: | 9:00 a.m. U.S. Eastern Time (ET) |
Event: | Fireside chat |
A replay of the presentations will also be accessible under the “Investors/Events” section www.novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts: InvestorsSilvia Taylor and Erika Trahanir@novavax.com240-268-2022
MediaBrandzone/KOGS CommunicationEdna Kaplankaplan@kogspr.com617-974-8659
1 Year Novavax Chart |
1 Month Novavax Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions